CLINICAL TRIALS PROFILE FOR PROMETH PLAIN

All Clinical Trials for PROMETH PLAIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02473042 ↗	Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)	Active, not recruiting	M.D. Anderson Cancer Center	N/A	2016-02-01	The goal of this clinical research study is to learn if light electrical stimulation to the wrist area during surgery is feasible in women having breast surgery.

Clinical Trial Conditions for PROMETH PLAIN

Condition Name

Condition Name for PROMETH PLAIN
Intervention	Trials
Post-Operative Nausea and Vomiting	1
Breast Cancer	1

Condition MeSH

Condition MeSH for PROMETH PLAIN
Intervention	Trials
Vomiting	1
Postoperative Nausea and Vomiting	1
Nausea	1
Breast Neoplasms	1

Clinical Trial Locations for PROMETH PLAIN

Trials by Country

Trials by Country for PROMETH PLAIN
Location	Trials
United States	1

Trials by US State

Trials by US State for PROMETH PLAIN
Location	Trials
Texas	1

Clinical Trial Progress for PROMETH PLAIN

Clinical Trial Phase

Clinical Trial Phase for PROMETH PLAIN
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for PROMETH PLAIN
Clinical Trial Phase	Trials
Active, not recruiting	1

Clinical Trial Sponsors for PROMETH PLAIN

Sponsor Name

Sponsor Name for PROMETH PLAIN
Sponsor	Trials
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for PROMETH PLAIN
Sponsor	Trials
Other	1

Last updated: May 1, 2026

Clinical Trials Update, Market Analysis, and Projection for Prometh Plain

No results found in the provided prompt for a drug identified as “PROMETH PLAIN.” As a result, there is no verifiable clinical-trials, market, or projection dataset to analyze.

What clinical trials data exists for “Prometh Plain”?

No clinical-trials record can be produced from the information provided.

What market data exists for “Prometh Plain”?

No market sizing inputs, sales history, approved indications, ATC/therapeutic class, or pricing benchmarks can be cited from the information provided.

What market projection can be made for “Prometh Plain”?

No projection model can be built without an identifiable active ingredient, dosage form, route, jurisdictional approvals, trial phases, endpoints, and launch status.

---

Key Takeaways

• “Prometh Plain” cannot be mapped to a specific, citable drug identity (active ingredient, strength, dosage form, or regulatory designation).
• No clinical-trials update can be generated.
• No market analysis or forward projection can be produced from the provided input.

---

FAQs

1. Is “Prometh Plain” the name of an approved medicine?
   Not enough information is present to establish approval status or regulatory identity.

2. Which phase trials should be assessed for this drug?
   Clinical-trials phases cannot be identified without a drug identity.

3. What markets or geographies should be included in projections?
   Markets cannot be selected without confirmed indications and regulatory status.

4. What benchmarks are used to project peak sales?
   Benchmarks require an identified drug and indication set.

5. Can you build a pipeline-to-revenue model from this prompt?
   A model requires trial and regulatory specifics that are not present.

---

References

No sources were provided or identifiable from the prompt.